We next tested whether avanafil, a PDE5 inhibitor previously shown to rescue ATP synthase deficiency caused by an MT-ATP6 missense mutation25, could restore the metabolic changes observed in mutant iPSC-MN. This evidence concerns the gene PDE5A and hyperinsulinemic hypoglycemia, familial, 4.